
    
      A 4-month, randomized, prospective, open-label comparison trial of 4 months of
      hydroxychloroquine vs. pioglitazone in type 2 diabetic patients inadequately controlled on
      maximally tolerated doses of metformin plus a sulfonylurea.
    
  